BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Refeyn - ECPv6.18.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Refeyn
X-ORIGINAL-URL:https://refeyn.com
X-WR-CALDESC:Events for Refeyn
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20260308T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20261101T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20270314T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20271107T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Tokyo
BEGIN:STANDARD
TZOFFSETFROM:+0900
TZOFFSETTO:+0900
TZNAME:JST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261013
DTEND;VALUE=DATE:20261016
DTSTAMP:20260529T152154Z
CREATED:20251203T214637Z
LAST-MODIFIED:20260529T152154Z
UID:10000010-1791849600-1792108799@refeyn.com
SUMMARY:Festival of Biologics - EU (Basel)
DESCRIPTION:Refeyn will continue its role in a project that has received additional funding through the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)\, focused on intelligent optimization of adeno-associated virus (AAV) purification processes.  NIIMBL brings together academia\, industry\, and government to fund collaborative projects tackling shared challenges in biopharmaceutical manufacturing – with the goal of driving down costs and accelerating the adoption of new technologies across the sector.   Gene therapy is an important area where potentially significant clinical reach remains constrained by manufacturing cost and complexity. Isolating AAV vectors with the purity\, potency\, and safety profiles required for therapeutic use is technically demanding. While upstream expression systems are rapidly improving\, purification remains a significant bottleneck\, driving up development costs and limiting accessibility.  The project Refeyn is part of\, Intelligent Affinity: Bayesian Optimization of Full AAV Purification Using Convective Affinity Adsorbents\, aims to address this issue directly.  By combining affinity membranes with a machine learning toolkit\, it will build a comprehensive database of purification data across AAV serotypes. This would give developers a searchable resource to identify the best starting point for purification method development\, reducing the time and resources spent on optimization.  Led by North Carolina State University\, the consortium also includes ChromaGenix\, EMD Millipore\, Genentech\, the University of North Carolina Chapel Hill\, and Waters Technologies. It is one of eight projects awarded under NIIMBL’s Project Call 9.1\, which allocated $9.7 million toward advancing domestic biopharmaceutical manufacturing.  Refeyn’s Samux® mass photometer is contributing at-line process analytical capability to the consortium. AAV purification development has historically required significant sample volumes and time-intensive methods to characterize capsid populations across different serotypes. SamuxMP addresses this by quantifying empty\, partially filled\, full and overfilled AAV capsids in minutes\, using minimal sample\, and with single-particle resolution. It enables faster\, more cost-effective optimization without compromising on the analytical quality needed to ensure product safety and potency.  Gabriella Kiss\, Refeyn’s Director of Market and Applications Development\, said: 								\n				\n				\n				\n									“AAV purification development faces a real analytical challenge – you need to characterize capsid populations accurately across multiple serotypes quickly and without consuming a large amount of sample. Mass photometry is well placed to meet that need. Its speed and low sample requirements mean development teams can move faster and at lower cost\, without sacrificing product quality or safety. Our consortium has made significant progress already\, and I look forward to seeing what we can achieve in this next phase.”  								\n				\n				\n				\n					The growing role of mass photometry in AAV characterization 				\n				\n				\n				\n									The NIIMBL funding represents confidence in mass photometry from the biopharmaceutical manufacturing sector. This is reinforced by parallel recognition from regulatory authorities and international standards bodies. It signals the technique’s importance in AAV bioprocessing – and its value in standardized\, harmonized approaches to AAV quality assessment.  Since 2024\, mass photometry has been recognized by multiple authoritative bodies. Most recently\, the ISO standard for Biotechnology – Gene Delivery Systems (16921-2) listed mass photometry as an approved method for determining AAV capsid content.   In 2025\, the US Pharmacopeia (USP) referenced mass photometry in its USP general chapter <1067>\, “Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus Gene Therapy Products”. The chapter highlights mass photometry – alongside AUC and TEM – as an orthogonal method capable of distinguishing between empty\, full\, and also partially filled capsids. USP also designated mass photometry as a key method for characterizing its new AAV reference standards.     Also in 2025\, China’s National Institutes for Food and Drug Control endorsed mass photometry as a robust method for AAV characterization.   In 2024\, the British Pharmacopeia included mass photometry in its Advanced Therapy Medicinal Products Guidance on Characterisation of the Capsid Particle Population in rAAV Products\, describing it as a “viable option for at-line process monitoring.”  
URL:https://refeyn.com/events-calendar/festival-of-biologics-eu-basel
LOCATION:Festival of Biologics (EU)\, Hall 1\, Messe\, Basel\, 4005\, Switzerland
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://refeyn.com/wp-content/uploads/2025/12/Festival-of-Biologics.jpg
GEO:47.5638488502;7.60007011349
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Festival of Biologics (EU) Hall 1 Messe Basel 4005 Switzerland;X-APPLE-RADIUS=500;X-TITLE=Hall 1\, Messe:geo:7.60007011349,47.5638488502
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20261014T190000
DTEND;TZID=America/Denver:20261014T200000
DTSTAMP:20261008T082434Z
CREATED:20261008T082433Z
LAST-MODIFIED:20261008T082434Z
UID:10000049-1792004400-1792008000@refeyn.com
SUMMARY:Breaking the Bottleneck: Rapid Empty/Full AAV Capsid Analysis with Mass Photometry
DESCRIPTION:Refeyn will continue its role in a project that has received additional funding through the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)\, focused on intelligent optimization of adeno-associated virus (AAV) purification processes.  NIIMBL brings together academia\, industry\, and government to fund collaborative projects tackling shared challenges in biopharmaceutical manufacturing – with the goal of driving down costs and accelerating the adoption of new technologies across the sector.   Gene therapy is an important area where potentially significant clinical reach remains constrained by manufacturing cost and complexity. Isolating AAV vectors with the purity\, potency\, and safety profiles required for therapeutic use is technically demanding. While upstream expression systems are rapidly improving\, purification remains a significant bottleneck\, driving up development costs and limiting accessibility.  The project Refeyn is part of\, Intelligent Affinity: Bayesian Optimization of Full AAV Purification Using Convective Affinity Adsorbents\, aims to address this issue directly.  By combining affinity membranes with a machine learning toolkit\, it will build a comprehensive database of purification data across AAV serotypes. This would give developers a searchable resource to identify the best starting point for purification method development\, reducing the time and resources spent on optimization.  Led by North Carolina State University\, the consortium also includes ChromaGenix\, EMD Millipore\, Genentech\, the University of North Carolina Chapel Hill\, and Waters Technologies. It is one of eight projects awarded under NIIMBL’s Project Call 9.1\, which allocated $9.7 million toward advancing domestic biopharmaceutical manufacturing.  Refeyn’s Samux® mass photometer is contributing at-line process analytical capability to the consortium. AAV purification development has historically required significant sample volumes and time-intensive methods to characterize capsid populations across different serotypes. SamuxMP addresses this by quantifying empty\, partially filled\, full and overfilled AAV capsids in minutes\, using minimal sample\, and with single-particle resolution. It enables faster\, more cost-effective optimization without compromising on the analytical quality needed to ensure product safety and potency.  Gabriella Kiss\, Refeyn’s Director of Market and Applications Development\, said: 								\n				\n				\n				\n									“AAV purification development faces a real analytical challenge – you need to characterize capsid populations accurately across multiple serotypes quickly and without consuming a large amount of sample. Mass photometry is well placed to meet that need. Its speed and low sample requirements mean development teams can move faster and at lower cost\, without sacrificing product quality or safety. Our consortium has made significant progress already\, and I look forward to seeing what we can achieve in this next phase.”  								\n				\n				\n				\n					The growing role of mass photometry in AAV characterization 				\n				\n				\n				\n									The NIIMBL funding represents confidence in mass photometry from the biopharmaceutical manufacturing sector. This is reinforced by parallel recognition from regulatory authorities and international standards bodies. It signals the technique’s importance in AAV bioprocessing – and its value in standardized\, harmonized approaches to AAV quality assessment.  Since 2024\, mass photometry has been recognized by multiple authoritative bodies. Most recently\, the ISO standard for Biotechnology – Gene Delivery Systems (16921-2) listed mass photometry as an approved method for determining AAV capsid content.   In 2025\, the US Pharmacopeia (USP) referenced mass photometry in its USP general chapter <1067>\, “Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus Gene Therapy Products”. The chapter highlights mass photometry – alongside AUC and TEM – as an orthogonal method capable of distinguishing between empty\, full\, and also partially filled capsids. USP also designated mass photometry as a key method for characterizing its new AAV reference standards.     Also in 2025\, China’s National Institutes for Food and Drug Control endorsed mass photometry as a robust method for AAV characterization.   In 2024\, the British Pharmacopeia included mass photometry in its Advanced Therapy Medicinal Products Guidance on Characterisation of the Capsid Particle Population in rAAV Products\, describing it as a “viable option for at-line process monitoring.”  
URL:https://refeyn.com/events-calendar/breaking-the-bottleneck-rapid-empty-full-aav-capsid-analysis-with-mass-photometry
LOCATION:Virtual Event\, MA\, United States
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://refeyn.com/wp-content/uploads/2026/10/Labroots-logo.png
GEO:55.378051;-3.435973
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20261021T090000
DTEND;TZID=America/Denver:20261021T170000
DTSTAMP:20261013T101611Z
CREATED:20260901T142941Z
LAST-MODIFIED:20261013T101611Z
UID:10000040-1792573200-1792602000@refeyn.com
SUMMARY:Mass Photometry User Day at University of Copenhagen
DESCRIPTION:Refeyn will continue its role in a project that has received additional funding through the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)\, focused on intelligent optimization of adeno-associated virus (AAV) purification processes.  NIIMBL brings together academia\, industry\, and government to fund collaborative projects tackling shared challenges in biopharmaceutical manufacturing – with the goal of driving down costs and accelerating the adoption of new technologies across the sector.   Gene therapy is an important area where potentially significant clinical reach remains constrained by manufacturing cost and complexity. Isolating AAV vectors with the purity\, potency\, and safety profiles required for therapeutic use is technically demanding. While upstream expression systems are rapidly improving\, purification remains a significant bottleneck\, driving up development costs and limiting accessibility.  The project Refeyn is part of\, Intelligent Affinity: Bayesian Optimization of Full AAV Purification Using Convective Affinity Adsorbents\, aims to address this issue directly.  By combining affinity membranes with a machine learning toolkit\, it will build a comprehensive database of purification data across AAV serotypes. This would give developers a searchable resource to identify the best starting point for purification method development\, reducing the time and resources spent on optimization.  Led by North Carolina State University\, the consortium also includes ChromaGenix\, EMD Millipore\, Genentech\, the University of North Carolina Chapel Hill\, and Waters Technologies. It is one of eight projects awarded under NIIMBL’s Project Call 9.1\, which allocated $9.7 million toward advancing domestic biopharmaceutical manufacturing.  Refeyn’s Samux® mass photometer is contributing at-line process analytical capability to the consortium. AAV purification development has historically required significant sample volumes and time-intensive methods to characterize capsid populations across different serotypes. SamuxMP addresses this by quantifying empty\, partially filled\, full and overfilled AAV capsids in minutes\, using minimal sample\, and with single-particle resolution. It enables faster\, more cost-effective optimization without compromising on the analytical quality needed to ensure product safety and potency.  Gabriella Kiss\, Refeyn’s Director of Market and Applications Development\, said: 								\n				\n				\n				\n									“AAV purification development faces a real analytical challenge – you need to characterize capsid populations accurately across multiple serotypes quickly and without consuming a large amount of sample. Mass photometry is well placed to meet that need. Its speed and low sample requirements mean development teams can move faster and at lower cost\, without sacrificing product quality or safety. Our consortium has made significant progress already\, and I look forward to seeing what we can achieve in this next phase.”  								\n				\n				\n				\n					The growing role of mass photometry in AAV characterization 				\n				\n				\n				\n									The NIIMBL funding represents confidence in mass photometry from the biopharmaceutical manufacturing sector. This is reinforced by parallel recognition from regulatory authorities and international standards bodies. It signals the technique’s importance in AAV bioprocessing – and its value in standardized\, harmonized approaches to AAV quality assessment.  Since 2024\, mass photometry has been recognized by multiple authoritative bodies. Most recently\, the ISO standard for Biotechnology – Gene Delivery Systems (16921-2) listed mass photometry as an approved method for determining AAV capsid content.   In 2025\, the US Pharmacopeia (USP) referenced mass photometry in its USP general chapter <1067>\, “Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus Gene Therapy Products”. The chapter highlights mass photometry – alongside AUC and TEM – as an orthogonal method capable of distinguishing between empty\, full\, and also partially filled capsids. USP also designated mass photometry as a key method for characterizing its new AAV reference standards.     Also in 2025\, China’s National Institutes for Food and Drug Control endorsed mass photometry as a robust method for AAV characterization.   In 2024\, the British Pharmacopeia included mass photometry in its Advanced Therapy Medicinal Products Guidance on Characterisation of the Capsid Particle Population in rAAV Products\, describing it as a “viable option for at-line process monitoring.”  
URL:https://refeyn.com/events-calendar/mass-photometry-user-day-at-university-of-copenhagen
LOCATION:University of Copenhagen\, Nørregade 10\, København\, Denmark\, 1165\, France
CATEGORIES:Trade Show
ATTACH;FMTTYPE=image/png:https://refeyn.com/wp-content/uploads/2026/08/images.png
GEO:55.680292099;12.571539755
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=University of Copenhagen Nørregade 10 København Denmark 1165 France;X-APPLE-RADIUS=500;X-TITLE=Nørregade 10:geo:12.571539755,55.680292099
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20261022T160000
DTEND;TZID=Europe/London:20261022T170000
DTSTAMP:20261002T101538Z
CREATED:20261002T093642Z
LAST-MODIFIED:20261002T101538Z
UID:10000045-1792684800-1792688400@refeyn.com
SUMMARY:Faster Decisions in AAV Process Development: Monolithic Chromatography Meets Mass Photometry
DESCRIPTION:Refeyn will continue its role in a project that has received additional funding through the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)\, focused on intelligent optimization of adeno-associated virus (AAV) purification processes.  NIIMBL brings together academia\, industry\, and government to fund collaborative projects tackling shared challenges in biopharmaceutical manufacturing – with the goal of driving down costs and accelerating the adoption of new technologies across the sector.   Gene therapy is an important area where potentially significant clinical reach remains constrained by manufacturing cost and complexity. Isolating AAV vectors with the purity\, potency\, and safety profiles required for therapeutic use is technically demanding. While upstream expression systems are rapidly improving\, purification remains a significant bottleneck\, driving up development costs and limiting accessibility.  The project Refeyn is part of\, Intelligent Affinity: Bayesian Optimization of Full AAV Purification Using Convective Affinity Adsorbents\, aims to address this issue directly.  By combining affinity membranes with a machine learning toolkit\, it will build a comprehensive database of purification data across AAV serotypes. This would give developers a searchable resource to identify the best starting point for purification method development\, reducing the time and resources spent on optimization.  Led by North Carolina State University\, the consortium also includes ChromaGenix\, EMD Millipore\, Genentech\, the University of North Carolina Chapel Hill\, and Waters Technologies. It is one of eight projects awarded under NIIMBL’s Project Call 9.1\, which allocated $9.7 million toward advancing domestic biopharmaceutical manufacturing.  Refeyn’s Samux® mass photometer is contributing at-line process analytical capability to the consortium. AAV purification development has historically required significant sample volumes and time-intensive methods to characterize capsid populations across different serotypes. SamuxMP addresses this by quantifying empty\, partially filled\, full and overfilled AAV capsids in minutes\, using minimal sample\, and with single-particle resolution. It enables faster\, more cost-effective optimization without compromising on the analytical quality needed to ensure product safety and potency.  Gabriella Kiss\, Refeyn’s Director of Market and Applications Development\, said: 								\n				\n				\n				\n									“AAV purification development faces a real analytical challenge – you need to characterize capsid populations accurately across multiple serotypes quickly and without consuming a large amount of sample. Mass photometry is well placed to meet that need. Its speed and low sample requirements mean development teams can move faster and at lower cost\, without sacrificing product quality or safety. Our consortium has made significant progress already\, and I look forward to seeing what we can achieve in this next phase.”  								\n				\n				\n				\n					The growing role of mass photometry in AAV characterization 				\n				\n				\n				\n									The NIIMBL funding represents confidence in mass photometry from the biopharmaceutical manufacturing sector. This is reinforced by parallel recognition from regulatory authorities and international standards bodies. It signals the technique’s importance in AAV bioprocessing – and its value in standardized\, harmonized approaches to AAV quality assessment.  Since 2024\, mass photometry has been recognized by multiple authoritative bodies. Most recently\, the ISO standard for Biotechnology – Gene Delivery Systems (16921-2) listed mass photometry as an approved method for determining AAV capsid content.   In 2025\, the US Pharmacopeia (USP) referenced mass photometry in its USP general chapter <1067>\, “Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus Gene Therapy Products”. The chapter highlights mass photometry – alongside AUC and TEM – as an orthogonal method capable of distinguishing between empty\, full\, and also partially filled capsids. USP also designated mass photometry as a key method for characterizing its new AAV reference standards.     Also in 2025\, China’s National Institutes for Food and Drug Control endorsed mass photometry as a robust method for AAV characterization.   In 2024\, the British Pharmacopeia included mass photometry in its Advanced Therapy Medicinal Products Guidance on Characterisation of the Capsid Particle Population in rAAV Products\, describing it as a “viable option for at-line process monitoring.”  
URL:https://refeyn.com/events-calendar/faster-decisions-in-aav-process-development-monolithic-chromatography-meets-mass-photometry
LOCATION:Virtual Event\, MA\, United States
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://refeyn.com/wp-content/uploads/2026/10/Matt-and-Cedric-webinar.jpg
GEO:55.378051;-3.435973
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20261027T160000
DTEND;TZID=Europe/London:20261027T170000
DTSTAMP:20261002T102208Z
CREATED:20261002T102158Z
LAST-MODIFIED:20261002T102208Z
UID:10000046-1793116800-1793120400@refeyn.com
SUMMARY:Seeing the Unseen: Revealing Immune Complex Formation and Antibody Aggregation with Mass Photometry
DESCRIPTION:Refeyn will continue its role in a project that has received additional funding through the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)\, focused on intelligent optimization of adeno-associated virus (AAV) purification processes.  NIIMBL brings together academia\, industry\, and government to fund collaborative projects tackling shared challenges in biopharmaceutical manufacturing – with the goal of driving down costs and accelerating the adoption of new technologies across the sector.   Gene therapy is an important area where potentially significant clinical reach remains constrained by manufacturing cost and complexity. Isolating AAV vectors with the purity\, potency\, and safety profiles required for therapeutic use is technically demanding. While upstream expression systems are rapidly improving\, purification remains a significant bottleneck\, driving up development costs and limiting accessibility.  The project Refeyn is part of\, Intelligent Affinity: Bayesian Optimization of Full AAV Purification Using Convective Affinity Adsorbents\, aims to address this issue directly.  By combining affinity membranes with a machine learning toolkit\, it will build a comprehensive database of purification data across AAV serotypes. This would give developers a searchable resource to identify the best starting point for purification method development\, reducing the time and resources spent on optimization.  Led by North Carolina State University\, the consortium also includes ChromaGenix\, EMD Millipore\, Genentech\, the University of North Carolina Chapel Hill\, and Waters Technologies. It is one of eight projects awarded under NIIMBL’s Project Call 9.1\, which allocated $9.7 million toward advancing domestic biopharmaceutical manufacturing.  Refeyn’s Samux® mass photometer is contributing at-line process analytical capability to the consortium. AAV purification development has historically required significant sample volumes and time-intensive methods to characterize capsid populations across different serotypes. SamuxMP addresses this by quantifying empty\, partially filled\, full and overfilled AAV capsids in minutes\, using minimal sample\, and with single-particle resolution. It enables faster\, more cost-effective optimization without compromising on the analytical quality needed to ensure product safety and potency.  Gabriella Kiss\, Refeyn’s Director of Market and Applications Development\, said: 								\n				\n				\n				\n									“AAV purification development faces a real analytical challenge – you need to characterize capsid populations accurately across multiple serotypes quickly and without consuming a large amount of sample. Mass photometry is well placed to meet that need. Its speed and low sample requirements mean development teams can move faster and at lower cost\, without sacrificing product quality or safety. Our consortium has made significant progress already\, and I look forward to seeing what we can achieve in this next phase.”  								\n				\n				\n				\n					The growing role of mass photometry in AAV characterization 				\n				\n				\n				\n									The NIIMBL funding represents confidence in mass photometry from the biopharmaceutical manufacturing sector. This is reinforced by parallel recognition from regulatory authorities and international standards bodies. It signals the technique’s importance in AAV bioprocessing – and its value in standardized\, harmonized approaches to AAV quality assessment.  Since 2024\, mass photometry has been recognized by multiple authoritative bodies. Most recently\, the ISO standard for Biotechnology – Gene Delivery Systems (16921-2) listed mass photometry as an approved method for determining AAV capsid content.   In 2025\, the US Pharmacopeia (USP) referenced mass photometry in its USP general chapter <1067>\, “Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus Gene Therapy Products”. The chapter highlights mass photometry – alongside AUC and TEM – as an orthogonal method capable of distinguishing between empty\, full\, and also partially filled capsids. USP also designated mass photometry as a key method for characterizing its new AAV reference standards.     Also in 2025\, China’s National Institutes for Food and Drug Control endorsed mass photometry as a robust method for AAV characterization.   In 2024\, the British Pharmacopeia included mass photometry in its Advanced Therapy Medicinal Products Guidance on Characterisation of the Capsid Particle Population in rAAV Products\, describing it as a “viable option for at-line process monitoring.”  
URL:https://refeyn.com/events-calendar/seeing-the-unseen-revealing-immune-complex-formation-and-antibody-aggregation-with-mass-photometry
LOCATION:Virtual Event\, MA\, United States
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://refeyn.com/wp-content/uploads/2026/10/Fabian-and-brenda-webinar.jpg
GEO:55.378051;-3.435973
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Tokyo:20261029T080000
DTEND;TZID=Asia/Tokyo:20261029T170000
DTSTAMP:20260707T151501Z
CREATED:20260622T152710Z
LAST-MODIFIED:20260707T151501Z
UID:10000038-1793260800-1793293200@refeyn.com
SUMMARY:Asia-Pacific Mass Photometry User Day
DESCRIPTION:Refeyn will continue its role in a project that has received additional funding through the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)\, focused on intelligent optimization of adeno-associated virus (AAV) purification processes.  NIIMBL brings together academia\, industry\, and government to fund collaborative projects tackling shared challenges in biopharmaceutical manufacturing – with the goal of driving down costs and accelerating the adoption of new technologies across the sector.   Gene therapy is an important area where potentially significant clinical reach remains constrained by manufacturing cost and complexity. Isolating AAV vectors with the purity\, potency\, and safety profiles required for therapeutic use is technically demanding. While upstream expression systems are rapidly improving\, purification remains a significant bottleneck\, driving up development costs and limiting accessibility.  The project Refeyn is part of\, Intelligent Affinity: Bayesian Optimization of Full AAV Purification Using Convective Affinity Adsorbents\, aims to address this issue directly.  By combining affinity membranes with a machine learning toolkit\, it will build a comprehensive database of purification data across AAV serotypes. This would give developers a searchable resource to identify the best starting point for purification method development\, reducing the time and resources spent on optimization.  Led by North Carolina State University\, the consortium also includes ChromaGenix\, EMD Millipore\, Genentech\, the University of North Carolina Chapel Hill\, and Waters Technologies. It is one of eight projects awarded under NIIMBL’s Project Call 9.1\, which allocated $9.7 million toward advancing domestic biopharmaceutical manufacturing.  Refeyn’s Samux® mass photometer is contributing at-line process analytical capability to the consortium. AAV purification development has historically required significant sample volumes and time-intensive methods to characterize capsid populations across different serotypes. SamuxMP addresses this by quantifying empty\, partially filled\, full and overfilled AAV capsids in minutes\, using minimal sample\, and with single-particle resolution. It enables faster\, more cost-effective optimization without compromising on the analytical quality needed to ensure product safety and potency.  Gabriella Kiss\, Refeyn’s Director of Market and Applications Development\, said: 								\n				\n				\n				\n									“AAV purification development faces a real analytical challenge – you need to characterize capsid populations accurately across multiple serotypes quickly and without consuming a large amount of sample. Mass photometry is well placed to meet that need. Its speed and low sample requirements mean development teams can move faster and at lower cost\, without sacrificing product quality or safety. Our consortium has made significant progress already\, and I look forward to seeing what we can achieve in this next phase.”  								\n				\n				\n				\n					The growing role of mass photometry in AAV characterization 				\n				\n				\n				\n									The NIIMBL funding represents confidence in mass photometry from the biopharmaceutical manufacturing sector. This is reinforced by parallel recognition from regulatory authorities and international standards bodies. It signals the technique’s importance in AAV bioprocessing – and its value in standardized\, harmonized approaches to AAV quality assessment.  Since 2024\, mass photometry has been recognized by multiple authoritative bodies. Most recently\, the ISO standard for Biotechnology – Gene Delivery Systems (16921-2) listed mass photometry as an approved method for determining AAV capsid content.   In 2025\, the US Pharmacopeia (USP) referenced mass photometry in its USP general chapter <1067>\, “Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus Gene Therapy Products”. The chapter highlights mass photometry – alongside AUC and TEM – as an orthogonal method capable of distinguishing between empty\, full\, and also partially filled capsids. USP also designated mass photometry as a key method for characterizing its new AAV reference standards.     Also in 2025\, China’s National Institutes for Food and Drug Control endorsed mass photometry as a robust method for AAV characterization.   In 2024\, the British Pharmacopeia included mass photometry in its Advanced Therapy Medicinal Products Guidance on Characterisation of the Capsid Particle Population in rAAV Products\, describing it as a “viable option for at-line process monitoring.”  
URL:https://refeyn.com/events-calendar/asia-pacific-mass-photometry-user-day
LOCATION:Asia-Pacific Mass Photometry User Day\, Sannomiya Convention Center\, One Knot Trades Bldg 5F\, 2-2-10 Isobe-dori\, Chuo-ku\, Kobe\, Hyogo\, 651-0084\, Japan
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://refeyn.com/wp-content/uploads/2026/06/2750447_AsiaMassPhotometryUserDayIllustrationBleed_052726.pdf.png
GEO:34.6902888719;135.199440182
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Asia-Pacific Mass Photometry User Day Sannomiya Convention Center One Knot Trades Bldg 5F 2-2-10 Isobe-dori Chuo-ku Kobe Hyogo 651-0084 Japan;X-APPLE-RADIUS=500;X-TITLE=Sannomiya Convention Center\, One Knot Trades Bldg 5F\, 2-2-10 Isobe-dori\, Chuo-ku:geo:135.199440182,34.6902888719
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20261108T120000
DTEND;TZID=America/Denver:20261110T220000
DTSTAMP:20260910T150224Z
CREATED:20260910T145625Z
LAST-MODIFIED:20260910T150224Z
UID:10000042-1794139200-1794348000@refeyn.com
SUMMARY:PSDI 2026: 34th Protein Structure Determination in Industry Meeting
DESCRIPTION:Refeyn will continue its role in a project that has received additional funding through the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)\, focused on intelligent optimization of adeno-associated virus (AAV) purification processes.  NIIMBL brings together academia\, industry\, and government to fund collaborative projects tackling shared challenges in biopharmaceutical manufacturing – with the goal of driving down costs and accelerating the adoption of new technologies across the sector.   Gene therapy is an important area where potentially significant clinical reach remains constrained by manufacturing cost and complexity. Isolating AAV vectors with the purity\, potency\, and safety profiles required for therapeutic use is technically demanding. While upstream expression systems are rapidly improving\, purification remains a significant bottleneck\, driving up development costs and limiting accessibility.  The project Refeyn is part of\, Intelligent Affinity: Bayesian Optimization of Full AAV Purification Using Convective Affinity Adsorbents\, aims to address this issue directly.  By combining affinity membranes with a machine learning toolkit\, it will build a comprehensive database of purification data across AAV serotypes. This would give developers a searchable resource to identify the best starting point for purification method development\, reducing the time and resources spent on optimization.  Led by North Carolina State University\, the consortium also includes ChromaGenix\, EMD Millipore\, Genentech\, the University of North Carolina Chapel Hill\, and Waters Technologies. It is one of eight projects awarded under NIIMBL’s Project Call 9.1\, which allocated $9.7 million toward advancing domestic biopharmaceutical manufacturing.  Refeyn’s Samux® mass photometer is contributing at-line process analytical capability to the consortium. AAV purification development has historically required significant sample volumes and time-intensive methods to characterize capsid populations across different serotypes. SamuxMP addresses this by quantifying empty\, partially filled\, full and overfilled AAV capsids in minutes\, using minimal sample\, and with single-particle resolution. It enables faster\, more cost-effective optimization without compromising on the analytical quality needed to ensure product safety and potency.  Gabriella Kiss\, Refeyn’s Director of Market and Applications Development\, said: 								\n				\n				\n				\n									“AAV purification development faces a real analytical challenge – you need to characterize capsid populations accurately across multiple serotypes quickly and without consuming a large amount of sample. Mass photometry is well placed to meet that need. Its speed and low sample requirements mean development teams can move faster and at lower cost\, without sacrificing product quality or safety. Our consortium has made significant progress already\, and I look forward to seeing what we can achieve in this next phase.”  								\n				\n				\n				\n					The growing role of mass photometry in AAV characterization 				\n				\n				\n				\n									The NIIMBL funding represents confidence in mass photometry from the biopharmaceutical manufacturing sector. This is reinforced by parallel recognition from regulatory authorities and international standards bodies. It signals the technique’s importance in AAV bioprocessing – and its value in standardized\, harmonized approaches to AAV quality assessment.  Since 2024\, mass photometry has been recognized by multiple authoritative bodies. Most recently\, the ISO standard for Biotechnology – Gene Delivery Systems (16921-2) listed mass photometry as an approved method for determining AAV capsid content.   In 2025\, the US Pharmacopeia (USP) referenced mass photometry in its USP general chapter <1067>\, “Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus Gene Therapy Products”. The chapter highlights mass photometry – alongside AUC and TEM – as an orthogonal method capable of distinguishing between empty\, full\, and also partially filled capsids. USP also designated mass photometry as a key method for characterizing its new AAV reference standards.     Also in 2025\, China’s National Institutes for Food and Drug Control endorsed mass photometry as a robust method for AAV characterization.   In 2024\, the British Pharmacopeia included mass photometry in its Advanced Therapy Medicinal Products Guidance on Characterisation of the Capsid Particle Population in rAAV Products\, describing it as a “viable option for at-line process monitoring.”  
URL:https://refeyn.com/events-calendar/psdi-2026
LOCATION:34th Protein Structure Determination in Industry Meeting\, Marstrands Havshotell\, Varvskajen 2\, 442 67 Marstrand\, Koön\, Sweden\, France
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://refeyn.com/wp-content/uploads/2026/09/34th-Protein-Structure-Determination-in-Industry-Meeting.jpg
GEO:57.8884502;11.5967453
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=34th Protein Structure Determination in Industry Meeting Marstrands Havshotell Varvskajen 2 442 67 Marstrand Koön Sweden France;X-APPLE-RADIUS=500;X-TITLE=Marstrands Havshotell\, Varvskajen 2\, 442 67 Marstrand:geo:11.5967453,57.8884502
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20261112T163000
DTEND;TZID=America/Denver:20261112T173000
DTSTAMP:20261008T082052Z
CREATED:20261008T082052Z
LAST-MODIFIED:20261008T082052Z
UID:10000048-1794501000-1794504600@refeyn.com
SUMMARY:Navigating Common Pitfalls in Gene Therapy Development
DESCRIPTION:Refeyn will continue its role in a project that has received additional funding through the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)\, focused on intelligent optimization of adeno-associated virus (AAV) purification processes.  NIIMBL brings together academia\, industry\, and government to fund collaborative projects tackling shared challenges in biopharmaceutical manufacturing – with the goal of driving down costs and accelerating the adoption of new technologies across the sector.   Gene therapy is an important area where potentially significant clinical reach remains constrained by manufacturing cost and complexity. Isolating AAV vectors with the purity\, potency\, and safety profiles required for therapeutic use is technically demanding. While upstream expression systems are rapidly improving\, purification remains a significant bottleneck\, driving up development costs and limiting accessibility.  The project Refeyn is part of\, Intelligent Affinity: Bayesian Optimization of Full AAV Purification Using Convective Affinity Adsorbents\, aims to address this issue directly.  By combining affinity membranes with a machine learning toolkit\, it will build a comprehensive database of purification data across AAV serotypes. This would give developers a searchable resource to identify the best starting point for purification method development\, reducing the time and resources spent on optimization.  Led by North Carolina State University\, the consortium also includes ChromaGenix\, EMD Millipore\, Genentech\, the University of North Carolina Chapel Hill\, and Waters Technologies. It is one of eight projects awarded under NIIMBL’s Project Call 9.1\, which allocated $9.7 million toward advancing domestic biopharmaceutical manufacturing.  Refeyn’s Samux® mass photometer is contributing at-line process analytical capability to the consortium. AAV purification development has historically required significant sample volumes and time-intensive methods to characterize capsid populations across different serotypes. SamuxMP addresses this by quantifying empty\, partially filled\, full and overfilled AAV capsids in minutes\, using minimal sample\, and with single-particle resolution. It enables faster\, more cost-effective optimization without compromising on the analytical quality needed to ensure product safety and potency.  Gabriella Kiss\, Refeyn’s Director of Market and Applications Development\, said: 								\n				\n				\n				\n									“AAV purification development faces a real analytical challenge – you need to characterize capsid populations accurately across multiple serotypes quickly and without consuming a large amount of sample. Mass photometry is well placed to meet that need. Its speed and low sample requirements mean development teams can move faster and at lower cost\, without sacrificing product quality or safety. Our consortium has made significant progress already\, and I look forward to seeing what we can achieve in this next phase.”  								\n				\n				\n				\n					The growing role of mass photometry in AAV characterization 				\n				\n				\n				\n									The NIIMBL funding represents confidence in mass photometry from the biopharmaceutical manufacturing sector. This is reinforced by parallel recognition from regulatory authorities and international standards bodies. It signals the technique’s importance in AAV bioprocessing – and its value in standardized\, harmonized approaches to AAV quality assessment.  Since 2024\, mass photometry has been recognized by multiple authoritative bodies. Most recently\, the ISO standard for Biotechnology – Gene Delivery Systems (16921-2) listed mass photometry as an approved method for determining AAV capsid content.   In 2025\, the US Pharmacopeia (USP) referenced mass photometry in its USP general chapter <1067>\, “Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus Gene Therapy Products”. The chapter highlights mass photometry – alongside AUC and TEM – as an orthogonal method capable of distinguishing between empty\, full\, and also partially filled capsids. USP also designated mass photometry as a key method for characterizing its new AAV reference standards.     Also in 2025\, China’s National Institutes for Food and Drug Control endorsed mass photometry as a robust method for AAV characterization.   In 2024\, the British Pharmacopeia included mass photometry in its Advanced Therapy Medicinal Products Guidance on Characterisation of the Capsid Particle Population in rAAV Products\, describing it as a “viable option for at-line process monitoring.”  
URL:https://refeyn.com/events-calendar/navigating-common-pitfalls-in-gene-therapy-development
LOCATION:Virtual Event\, MA\, United States
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://refeyn.com/wp-content/uploads/2026/10/Technology-network.png
GEO:55.378051;-3.435973
END:VEVENT
END:VCALENDAR